Similarly, AKT3 is up-regulated in T47D luminal breast cancer cells in response to the AKT inhibitor MK2206 that confers resistance to MK2206, and AKT3 depletion in these cells selectively increases sensitivity to MK2206 treatment whereas AKT1 or AKT2 depletion has no effect [69]. This evidence concerns the gene AKT3 and breast cancer.